Titration

Global Analytical Standards (GC, MS, LC, IR, NMR, Gravimetry) Market Research Report 2023: Increasing Public-Private Investments in Research to Drive Growth - Forecasts to 2028 - ResearchAndMarkets.com

Retrieved on: 
Friday, December 29, 2023
Retail, Health, Environment, Green Technology, Pharmaceutical, Food, Beverage, Category, Forensic science, Forecasting, NMR, Drug development, Research, Region, Titration, Organic, USD, GC, CRMS, Growth, Chromatography, Fine chemical

The global analytical standards market is projected to reach USD 2.1 billion by 2028 from USD 1.5 billion in 2023, growing at a CAGR of 6.9%

Key Points: 
  • The global analytical standards market is projected to reach USD 2.1 billion by 2028 from USD 1.5 billion in 2023, growing at a CAGR of 6.9%
    This report studies the analytical standards market based on technique, application, methodology, category, and region.
  • Additionally, development of new analytical methods affect the growth of analytical standards market.
  • Based on application, analytical standards is segmented into food & beverages standards, forensic standards, veterinary drug standards, environmental standards, petrochemistry standards and pharmaceutical & life science standards.
  • Organic analytical standards accounted for the largest share of the global analytical standards market in 2022.

InMed AI Receives FDA 510(k) clearance for NeuroShield™

Retrieved on: 
Monday, November 13, 2023
Brain, Food, Alzheimer's Disease Neuroimaging Initiative, US Foods, Parkinson's disease, Patient, Medicine, FDA, Neurology, Titration, Medicare, Patent, MRI, United States patent law, Physician, Quality of life, Radiology, Medical imaging, Pharmaceutical industry, Atrophy, Dementia, Epilepsy

CHICAGO, Nov. 13, 2023 /PRNewswire/ -- InMed.AI (InMed Prognostics Inc.), a pioneer in AI-driven predictive analytics using multi-modal data including text, signal, and image (US Patent No.11263749) and the creator of an end-to-end fully automated organ agnostic imaging platform, announced that it has received the US Food and Drug Administration (FDA) 510(k) clearance for NeuroShield™, a fully automated brain geometry-based quantifying analytics tool/cloud platform that uses AI/Deep Net/3D Convolutional Networks to support physicians as a clinical decision support tool for neurologists and neuroradiologists. NeuroShield is currently in clinical use in over 220+ sites across the world. In-Med is supported by seed funding from Sriram Natarajan, Founder & CEO of Molbio Diagnostics.

Key Points: 
  • In-Med is supported by seed funding from Sriram Natarajan, Founder & CEO of Molbio Diagnostics.
  • The segmentation analysis revealed remarkable accuracy, reliability, and effectiveness of NeuroShield.
  • In addition, it is recommended that patients using the new drugs undergo periodic scans to monitor for any side effectsii.
  • In-Med Prognostics has long recognized the critical role of inclusion and ethnicity in healthcare and is leading the charge in developing solutions tailored to diverse patient populations.

PASCO Scientific Launches Chemvue Software for University Labs

Retrieved on: 
Tuesday, August 15, 2023
Physics, Science, Intermolecular force, Chemistry, Titration, Student, PH, Temperature, Thermodynamics, Engineering, Instrumentation

ROSEVILLE, Calif., Aug. 15, 2023 (GLOBE NEWSWIRE) -- PASCO Scientific — the leading global provider of technology-enhanced solutions for physics, chemistry, engineering, and life science education, announces Chemvue , the next-generation chemistry software for university labs.

Key Points: 
  • ROSEVILLE, Calif., Aug. 15, 2023 (GLOBE NEWSWIRE) -- PASCO Scientific — the leading global provider of technology-enhanced solutions for physics, chemistry, engineering, and life science education, announces Chemvue , the next-generation chemistry software for university labs.
  • Students can now collect and analyze experiment data with the Chemvue app and PASCO’s popular wireless sensors — gas pressure, pH, temperature, and more.
  • “For many years, data-logging software had been designed to meet the need of all science students,” says Richard Briscoe former science educator and CEO of PASCO Scientific.
  • “At PASCO, we have found that higher-education chemistry labs require specific analytical features for laboratory instructors and their students.

Global Reaction Monitoring Market Forecast to 2032: Rising Public-private Investments in Life Science Research Drives Growth - ResearchAndMarkets.com

Retrieved on: 
Thursday, April 13, 2023
Other Science, Science, Biotechnology, Food safety, Growth, Chromatography, Food, Drug development, X-ray, Research, Investment, Titration, Calorimetry, Fine chemical

The strict regulatory standards in the pharmaceutical and biotechnology sectors, the development of the food and beverage sector, and rising public-private investments in life science research are factors contributing to the market growth.

Key Points: 
  • The strict regulatory standards in the pharmaceutical and biotechnology sectors, the development of the food and beverage sector, and rising public-private investments in life science research are factors contributing to the market growth.
  • Based on technology, the market is categorized into chromatography, spectroscopy, titrimetry, calorimetry, and x-ray diffraction.
  • Based on end user, the market is segmented into pollution monitoring & control industry, pharmaceutical-biotechnology companies, food & beverages industry, and life science & genomic research facilities.
  • In 2021, North America region accounted for the highest revenue in the reaction monitoring market and is expected to maintain its dominance during the forecast period.

Analytical Standards Market is expected to generate a revenue of USD 2.56 Billion by 2030, Globally, at 7.70% CAGR: Verified Market Research®

Retrieved on: 
Thursday, November 10, 2022
Paragon, USD, Carbon, Titration, Prevalence, Coma, Method, Market research, Depression, Geography, Food, Forensic science, LGC, Petroleum, Bharat Petroleum, Agilent Technologies, Merck, Adoption, Anxiety, Global analytic function, Population, Category, Death, PerkinElmer, Primary standard, Degenerative disease, Allergy, Infection, Secondary, Safety, Asthma, Government, Cancer, Food safety, Chromatography, Industry, Urinary tract infection, Food quality, Mass spectrometry, CAGR, Pharmaceutical industry

JERSEY CITY, N.J., Nov. 10, 2022 /PRNewswire/ -- Verified Market Research recently published a report, "Analytical Standards Market" By Techniques (Chromatography, Spectroscopy), By Category (Primary Standard, Secondary Standards), By Application (Food and beverage, Forensic Standards), By Geographic Scope And Forecast.

Key Points: 
  • JERSEY CITY, N.J., Nov. 10, 2022 /PRNewswire/ -- Verified Market Research recently published a report, " Analytical Standards Market " By Techniques (Chromatography, Spectroscopy), By Category (Primary Standard, Secondary Standards), By Application (Food and beverage, Forensic Standards), By Geographic Scope And Forecast.
  • As per the deep research carried out by Verified Market Research, the global Analytical Standards Market size was valued at USD 1.34 Billion in 2021 and is projected to reach USD 2.56 Billion by 2030, growing at a CAGR of 7.70% from 2022 to 2030.
  • A high-level vitality with a concentration that is used as a calibration standard for a particular experiment is known as an analytical standard.
  • Verified Market Research has segmented the Global Analytical Standards Market On the basis of Techniques, Category, Application, and Geography.

Analytical Standards Market is expected to generate a revenue of USD 2.56 Billion by 2030, Globally, at 7.70% CAGR: Verified Market Research®

Retrieved on: 
Thursday, November 10, 2022
Paragon, USD, Carbon, Titration, Prevalence, Coma, Method, Market research, Depression, Geography, Food, Forensic science, LGC, Petroleum, Bharat Petroleum, Agilent Technologies, Merck, Adoption, Anxiety, Global analytic function, Population, Category, Death, PerkinElmer, Primary standard, Degenerative disease, Allergy, Infection, Secondary, Safety, Asthma, Government, Cancer, Food safety, Chromatography, Industry, Urinary tract infection, Food quality, Mass spectrometry, CAGR, Pharmaceutical industry

JERSEY CITY, N.J., Nov. 10, 2022 /PRNewswire/ -- Verified Market Research recently published a report, "Analytical Standards Market" By Techniques (Chromatography, Spectroscopy), By Category (Primary Standard, Secondary Standards), By Application (Food and beverage, Forensic Standards), By Geographic Scope And Forecast.

Key Points: 
  • JERSEY CITY, N.J., Nov. 10, 2022 /PRNewswire/ -- Verified Market Research recently published a report, " Analytical Standards Market " By Techniques (Chromatography, Spectroscopy), By Category (Primary Standard, Secondary Standards), By Application (Food and beverage, Forensic Standards), By Geographic Scope And Forecast.
  • As per the deep research carried out by Verified Market Research, the global Analytical Standards Market size was valued at USD 1.34 Billion in 2021 and is projected to reach USD 2.56 Billion by 2030, growing at a CAGR of 7.70% from 2022 to 2030.
  • A high-level vitality with a concentration that is used as a calibration standard for a particular experiment is known as an analytical standard.
  • Verified Market Research has segmented the Global Analytical Standards Market On the basis of Techniques, Category, Application, and Geography.

Recordati Rare Diseases Announces Several Scientific Abstracts to Be Presented at the Upcoming Endo Society Annual Meeting

Retrieved on: 
Wednesday, June 8, 2022
Research, Clinical Trials, Biotechnology, Other Health, Health, Pharmaceutical, General Health, Other Science, Science, ENDO, QT interval, Plasma, Dizziness, Efficacy, Quality of life, Serum, Vomiting, ECG, Hypokalemia, Uncertainty, Hyperandrogenism, Infection, Barrow Neurological Institute, Headache, Advertising, Edema, Awareness, Half-life, Hypotension, Endocrine system, Hypoglycemia, Phase, Diagnosis, MD, Adrenal insufficiency, Patient, Degenerative disease, Hypertension, Nausea, Abdominal pain, Arrhythmia, Symptoms of COVID-19, Adrenocorticotropic hormone, Disease, Incidence, Androgen, Pituitary adenoma, Adult, Research, CYP3A4, Fatigue, Titration, Nature, ACTH, FDA, Mortality, CYP2B6, Risk, Magnesium, Lactation, QT, LINC, Pharmaceutical industry, Medical imaging, Birth control, Osilodrostat, Safety

Recordati Rare Diseases Inc. announced today that various scientific abstracts have been accepted and will be presented onsite at the ENDO 2022 annual meeting being held in Atlanta, Georgia from June 11 14, 2022.

Key Points: 
  • Recordati Rare Diseases Inc. announced today that various scientific abstracts have been accepted and will be presented onsite at the ENDO 2022 annual meeting being held in Atlanta, Georgia from June 11 14, 2022.
  • For more information visit www.isturisa.com
    About Recordati Rare Diseases Inc.
    Recordati Rare Diseases Inc. is a biopharmaceutical company committed to providing often-overlooked orphan therapies to the underserved rare disease communities of the United States.
  • Recordati Rare Diseases mission is to reduce the impact of extremely rare and devastating diseases by providing urgently needed therapies.
  • We work side-by-side with rare disease communities to increase awareness, improve diagnosis and expand availability of treatments for people with rare diseases.

The Worldwide Reaction Monitoring Industry is Expected to Reach $1.82 Billion by 2027 - ResearchAndMarkets.com

Retrieved on: 
Wednesday, December 29, 2021
Technology, Biotechnology, Packaging, Retail, Health, Manufacturing, Other Health, Pharmaceutical, Other Science, Environment, Other Technology, Science, Other Manufacturing, Food, Beverage, Growth, Industry, Global, Geography, Compliance, Porter's five forces analysis, CAGR, Medication, Investment, Observation, Miniaturization, Ansoff Matrix, Food, Biotechnology, Water pollution, X-ray scattering techniques, Chromatography, USD, Automation, COVID-19, Air pollution, Technology, Fine chemical, Calorimetry, Titration, Spectroscopy

The Global Reaction Monitoring Market is estimated to be USD 1.3 Bn in 2021 and is expected to reach USD 1.82 Bn by 2027, growing at a CAGR of 5.8%.

Key Points: 
  • The Global Reaction Monitoring Market is estimated to be USD 1.3 Bn in 2021 and is expected to reach USD 1.82 Bn by 2027, growing at a CAGR of 5.8%.
  • However, the high costs associated with analytical instruments and lack of skilled expertise may create hindrances in the growth of the Global Reaction Monitoring Market to a certain extent.
  • By Reaction Mode, the market is classified into Quantitative Monitoring and Qualitative Monitoring.
  • The report offers a comprehensive evaluation of the Global Reaction Monitoring Market.

LivaNova to Present Scientific Data on VNS Therapy for Drug-Resistant Epilepsy at American Epilepsy Society 2021 Annual Meeting

Retrieved on: 
Thursday, December 2, 2021
Research, Mental Health, Medical Devices, Clinical Trials, Other Health, Biotechnology, Alternative Medicine, General Health, Health, Science, People, Gaia, Comparison, Vagus nerve, Data mining, News, Pediatric neurosurgery, LGS, Risk, Postdoctoral researcher, Head, Conference, Annual report, Company, DBS, LivaNova, Vagus nerve stimulation, AES, Partnership, Seizure, LIVN, Anticonvulsant, Goal, Lennox–Gastaut syndrome, Annual general meeting, Hope, PLC, VNS, Research, Neurosurgery, American Epilepsy Society, RNS, DRE, FDA, Major trauma, Poster, Titration, Division, Catherine Disher, Doctor of Philosophy, Epilepsy, NASDAQ, Pharmaceutical industry, Medicine

The Company will present seven scientific posters aimed at engaging clinical collaborators and deepening understanding of the LivaNova VNS Therapy System for the treatment of drug-resistant epilepsy.

Key Points: 
  • The Company will present seven scientific posters aimed at engaging clinical collaborators and deepening understanding of the LivaNova VNS Therapy System for the treatment of drug-resistant epilepsy.
  • LivaNova pioneered the VNS Therapy System, which sends mild pulses to the vagus nerve via an implantable device.
  • The seven scientific poster presentations feature the work of LivaNova employees and/or independent investigators using the Companys VNS Therapy System in their research.
  • These statements include, but are not limited to, statements regarding participation in upcoming events and VNS Therapy for drug-resistant epilepsy.

OpGen Achieves Key Development Milestone in Unyvero A30 RQ Platform Program

Retrieved on: 
Tuesday, August 3, 2021
Transport in England, Laboratory techniques, Assay, Biochemistry, Titration, A30 road, Transport in the United Kingdom, A30, England

ROCKVILLE, Md., Aug. 03, 2021 (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq: OPGN, “OpGen”), a precision medicine company harnessing the power of molecular diagnostics and bioinformatics to help combat infectious disease, today announced that its subsidiary Curetis GmbH and its instrument development and engineering partner have assembled 10 final pre-series release analyzer instruments of the Unyvero A30 RQ platform. The assembly of the instruments marks the successful completion of a major development milestone in the Unyvero A30 program. The A30 RQ analyzers will now proceed into final verification and validation testing.

Key Points: 
  • The assembly of the instruments marks the successful completion of a major development milestone in the Unyvero A30 program.
  • Furthermore, the Unyvero A30 RQ platform can be made available to third party development and commercialization partners and licensees for their own assay menu and product portfolio.
  • The Unyvero A30 RQ platform is designed to allow straightforward migration of third party assays using well-established real time PCR technology.
  • This press release includes statements regarding the development of OpGens Unyvero A30 RQ platform.